Latest Medistem Inc. (MEDS) Headlines
Intrexon acquires San Diego-based Medistem
M2 - Mon Mar 10, 7:57AM CDT
US-based synthetic biology company Intrexon (NYSE:XON) announced on Friday the completion of the acquisition of Medistem (Other OTC:MEDS).
Intrexon Completes Acquisition of Medistem
PR Newswire - Fri Mar 07, 7:30AM CST
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has completed the acquisition of San Diego-based Medistem, Inc. (OTCQB: MEDS), a pioneer in the development of Endometrial Regenerative Cells ("ERC" or "ERCs"), universal donor adult-derived stem cells with properties uniquely suited for therapeutic use with Intrexon's existing suite of synthetic biology technologies. Upon integration of these platforms, ERCs could be manufactured as genetically modified vehicles to secrete powerful therapeutic effectors in the body for clinical benefit to patients suffering from many different diseases.
CounterPath to Present at Needham Growth Conference
Marketwire Canada - Thu Jan 09, 6:57PM CST
CounterPath Corporation (NASDAQ:CPAH)(TSX:CCV), an award-winning provider of desktop and mobile VoIP software products and solutions, announces that Donovan Jones, President and Chief Executive Officer, will present at the 16th Annual Needham Growth Conference. Mr. Jones will outline CounterPath's VoIP software and services, its customer relationships, its IP portfolio and the sector outlook.
SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Medistem, Inc. - MEDS
PR Newswire - Wed Jan 08, 2:51PM CST
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Medistem, Inc. ("Medistem" or the "Company") (OTC Markets: MEDS) relating to the proposed acquisition of Intrexon Corporation. ("Intrexon").
MEDISTEM INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
Business Wire - Sun Jan 05, 3:41PM CST
Rigrodsky & Long, P.A.:
INVESTOR ALERT Levi & Korsinsky, LLP Announces Investigation of Medistem, Inc. and Its Board of Directors in Connection with the Sale of the Company to Intrexon Corporation
Business Wire - Fri Dec 20, 2:00PM CST
Levi & Korsinsky is investigating the Board of Directors of Medistem, Inc. ("Medistem" or "the Company") (OTCQB:MEDS) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Intrexon Corporation ("Intrexon").
Medistem Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Acquisition by Intrexon
Business Wire - Fri Dec 20, 10:10AM CST
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Medistem, Inc. (OTCBB: MEDS) related to the acquisition by Intrexon Corporation for shareholders. Under the terms of the definitive agreement valued at approximately $26 million, Medistem shareholders will only receive $0.27 in cash and $1.08 worth of Intrexon common stock for each share of MEDS stock owned, well below the 52-week high of $2.80.
Intrexon to Acquire Medistem to Generate Multipotent Cells
GlobeNewswire - Fri Dec 20, 9:44AM CST
Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced that it has entered into a definitive agreement to acquire, for approximately $26 million, San Diego-based Medistem, Inc. (OTCQB:MEDS) a pioneer in the development of Endometrial Regenerative Cells ("ERC" or "ERCs"), universal donor adult stem cells that stimulate new blood vessel formation and are capable of generating different tissues including heart, brain, pancreas, liver, bone, cartilage and lung. Intrexon intends to employ its integrated synthetic biology platforms to engineer a diverse array of cell-based therapeutic candidates using Medistem's multipotent ERCs.
Oxford Immunotec Global PLC Announces Appointment of Herm Rosenman to the Board of Directors
Business Wire - Mon Dec 02, 11:47AM CST
Oxford Immunotec Global PLC (NASDAQ: OXFD) (the "Company") announced today that Herman ("Herm") Rosenman has been appointed as a member of the Company's Board of Directors and will serve as Chairman of the Board's Audit Committee. Mr. Rosenman served most recently as Senior Vice President, Finance and Chief Financial Officer of Gen-Probe Incorporated, a publicly traded molecular diagnostics company, which was acquired by Hologic, Inc. in 2012. He is currently a member of the Board of Directors and Audit Committee Chairman of Vivus, Inc., a publicly traded biopharmaceutical company, Medistem, Inc., a stem cell therapy company, and BioFire Diagnostics, Inc., a molecular diagnostics company. "Herm brings significant experience to our Board of Directors based upon his past positions as both a senior executive and a director of companies in the diagnostics and healthcare sectors," commented Peter Wrighton-Smith, Ph.D., the Company's Chief Executive Officer. "We are delighted to have Herm join the Board and look forward to working with him to build the Company."
Medistem Begins Trading on the OTCQB
GlobeNewswire - Thu Nov 14, 8:00AM CST
Medistem Inc. (OTCQB:MEDS), today announced that its shares of common stock are now listed on the OTC Markets Group's OTCQB marketplace. The company's shares were previously listed on the Pinksheets.
Medistem Announces Patent Application on Stem Cell Secreted Nanoparticles (Exosomes)
Marketwire - Thu Aug 15, 8:01AM CDT
Medistem, Inc. (PINKSHEETS: MEDS), announced today the publication of a patent application entitled "Therapeutic Immune Modulation by Stem Cell Secreted Exosomes." The patent application covers the use of stem cell derived nanoparticles, termed "exosomes", for the treatment of autoimmune conditions, including Type 1 Diabetes, multiple sclerosis, rheumatoid arthritis, and lupus.
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2013 Out Now
M2 - Thu Aug 08, 11:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2j8flq/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD). Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD). - A review of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AnGes MG, Inc. - Arena Pharmaceuticals, Inc. - AstraZeneca PLC - Athera Biotechnologies AB - Athersys, Inc. - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Cytokinetics, Inc - DNAVEC Corporation - Diffusion Pharmaceuticals LLC - F. Hoffmann-La Roche Ltd. - Medistem, Inc. - Mesoblast Ltd - miRagen Therapeutics, Inc. - Nissan Chemical Industries, Ltd. - Proteon Therapeutics, Inc. - ReNeuron Group plc - RegenoCELL Therapeutics, Inc. - Sigma-Tau S.p.A. - Synthon BV - Theravasc, Inc. - Viromed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2j8flq/peripheral About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Medistem Presents Its ERC-124 Stem Cell Product at CRYO 2013
Marketwire - Wed Jul 31, 8:02AM CDT
Medistem, Inc. (PINKSHEETS: MEDS), announced today it's President and Chief Scientific Officer, Thomas E. Ichim, Ph.D., presented at the CRYO 2013 Conference held in Bethesda, Maryland on Monday July 29th.
Medistem Enters Collaboration With Boston Academic Teaching Hospital to Expand Preclinical Data in Type 1 Diabetes
Marketwire - Mon Jul 29, 8:01AM CDT
Medistem, Inc. (PINKSHEETS: MEDS) announced today it has entered into collaboration with Reza Abdi, M.D., Transplant Nephrologist at Brigham and Women's Hospital and Assistant Professor of Medicine, Harvard Medical School. Under the collaboration, the Company will provide Dr. Abdi with its Endometrial Regenerative Cells (ERCs) and it is expected that his research would support FDA clearance to initiate clinical trials to use ERCs as a treatment for Type 1 Diabetes. Currently, the Company has FDA clearance to initiate a dose-escalating Phase I clinical trial to use ERCs in patients with critical limb ischemia, a complication of diabetes.
Reminder -- Medistem to Host Investor Update Conference Call
Marketwire - Thu Jul 25, 8:02AM CDT
Medistem, Inc. (PINKSHEETS: MEDS), reminds investors that its Chief Executive Officer, Alan J. Lewis, Ph.D., will host a conference call today at 4:30 pm Eastern time (1:30 pm Pacific time). Dr. Lewis will provide a business update and discuss the Company's plans. Investors may participate either by phone or audio webcast.
Medistem Inc signs licensing agreement with Cytori Therapeutics Inc for autoimmune diseases
M2 - Fri Jul 19, 8:59AM CDT
Adult stem cell product company Medistem Inc (PINKSHEETS:MEDS) revealed on Thursday that it has licensed its exclusive rights to US Patent No. 8,241,621.
Medistem to Host Investor Update Conference Call
Marketwire - Fri Jul 19, 8:00AM CDT
Medistem, Inc. (PINKSHEETS: MEDS) today announced that Alan J. Lewis, Ph.D., the Company's Chief Executive Officer, will host a conference call at 4:30 pm Eastern time (1:30 pm Pacific time) on July 25, 2013. Dr. Lewis will provide a business update and discuss the Company's plans. Investors may participate either by phone or audio webcast.
Medistem and Cytori Therapeutics Enter Into Licensing Agreement
Marketwire - Thu Jul 18, 8:02AM CDT
Medistem, Inc. (PINKSHEETS: MEDS), today announced that it entered into an agreement granting Cytori Therapeutics, Inc. (NASDAQ: CYTX) a license and the exclusive rights to use Medistem's U.S. Patent No. 8,241,621, "Stem Cell Mediated Treg Activation" in the United States.
Intrexon acquires San Diego-based Medistem
M2 - Mon Mar 10, 7:57AM CDT
US-based synthetic biology company Intrexon (NYSE:XON) announced on Friday the completion of the acquisition of Medistem (Other OTC:MEDS).
Intrexon Completes Acquisition of Medistem
PR Newswire - Fri Mar 07, 7:30AM CST
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has completed the acquisition of San Diego-based Medistem, Inc. (OTCQB: MEDS), a pioneer in the development of Endometrial Regenerative Cells ("ERC" or "ERCs"), universal donor adult-derived stem cells with properties uniquely suited for therapeutic use with Intrexon's existing suite of synthetic biology technologies. Upon integration of these platforms, ERCs could be manufactured as genetically modified vehicles to secrete powerful therapeutic effectors in the body for clinical benefit to patients suffering from many different diseases.
CounterPath to Present at Needham Growth Conference
Marketwire Canada - Thu Jan 09, 6:57PM CST
CounterPath Corporation (NASDAQ:CPAH)(TSX:CCV), an award-winning provider of desktop and mobile VoIP software products and solutions, announces that Donovan Jones, President and Chief Executive Officer, will present at the 16th Annual Needham Growth Conference. Mr. Jones will outline CounterPath's VoIP software and services, its customer relationships, its IP portfolio and the sector outlook.
SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Medistem, Inc. - MEDS
PR Newswire - Wed Jan 08, 2:51PM CST
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Medistem, Inc. ("Medistem" or the "Company") (OTC Markets: MEDS) relating to the proposed acquisition of Intrexon Corporation. ("Intrexon").
MEDISTEM INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
Business Wire - Sun Jan 05, 3:41PM CST
Rigrodsky & Long, P.A.:
INVESTOR ALERT Levi & Korsinsky, LLP Announces Investigation of Medistem, Inc. and Its Board of Directors in Connection with the Sale of the Company to Intrexon Corporation
Business Wire - Fri Dec 20, 2:00PM CST
Levi & Korsinsky is investigating the Board of Directors of Medistem, Inc. ("Medistem" or "the Company") (OTCQB:MEDS) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Intrexon Corporation ("Intrexon").
Medistem Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Acquisition by Intrexon
Business Wire - Fri Dec 20, 10:10AM CST
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Medistem, Inc. (OTCBB: MEDS) related to the acquisition by Intrexon Corporation for shareholders. Under the terms of the definitive agreement valued at approximately $26 million, Medistem shareholders will only receive $0.27 in cash and $1.08 worth of Intrexon common stock for each share of MEDS stock owned, well below the 52-week high of $2.80.
Intrexon to Acquire Medistem to Generate Multipotent Cells
GlobeNewswire - Fri Dec 20, 9:44AM CST
Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced that it has entered into a definitive agreement to acquire, for approximately $26 million, San Diego-based Medistem, Inc. (OTCQB:MEDS) a pioneer in the development of Endometrial Regenerative Cells ("ERC" or "ERCs"), universal donor adult stem cells that stimulate new blood vessel formation and are capable of generating different tissues including heart, brain, pancreas, liver, bone, cartilage and lung. Intrexon intends to employ its integrated synthetic biology platforms to engineer a diverse array of cell-based therapeutic candidates using Medistem's multipotent ERCs.
Oxford Immunotec Global PLC Announces Appointment of Herm Rosenman to the Board of Directors
Business Wire - Mon Dec 02, 11:47AM CST
Oxford Immunotec Global PLC (NASDAQ: OXFD) (the "Company") announced today that Herman ("Herm") Rosenman has been appointed as a member of the Company's Board of Directors and will serve as Chairman of the Board's Audit Committee. Mr. Rosenman served most recently as Senior Vice President, Finance and Chief Financial Officer of Gen-Probe Incorporated, a publicly traded molecular diagnostics company, which was acquired by Hologic, Inc. in 2012. He is currently a member of the Board of Directors and Audit Committee Chairman of Vivus, Inc., a publicly traded biopharmaceutical company, Medistem, Inc., a stem cell therapy company, and BioFire Diagnostics, Inc., a molecular diagnostics company. "Herm brings significant experience to our Board of Directors based upon his past positions as both a senior executive and a director of companies in the diagnostics and healthcare sectors," commented Peter Wrighton-Smith, Ph.D., the Company's Chief Executive Officer. "We are delighted to have Herm join the Board and look forward to working with him to build the Company."
Medistem Begins Trading on the OTCQB
GlobeNewswire - Thu Nov 14, 8:00AM CST
Medistem Inc. (OTCQB:MEDS), today announced that its shares of common stock are now listed on the OTC Markets Group's OTCQB marketplace. The company's shares were previously listed on the Pinksheets.
Medistem Announces Patent Application on Stem Cell Secreted Nanoparticles (Exosomes)
Marketwire - Thu Aug 15, 8:01AM CDT
Medistem, Inc. (PINKSHEETS: MEDS), announced today the publication of a patent application entitled "Therapeutic Immune Modulation by Stem Cell Secreted Exosomes." The patent application covers the use of stem cell derived nanoparticles, termed "exosomes", for the treatment of autoimmune conditions, including Type 1 Diabetes, multiple sclerosis, rheumatoid arthritis, and lupus.
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2013 Out Now
M2 - Thu Aug 08, 11:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2j8flq/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD). Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD). - A review of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AnGes MG, Inc. - Arena Pharmaceuticals, Inc. - AstraZeneca PLC - Athera Biotechnologies AB - Athersys, Inc. - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Cytokinetics, Inc - DNAVEC Corporation - Diffusion Pharmaceuticals LLC - F. Hoffmann-La Roche Ltd. - Medistem, Inc. - Mesoblast Ltd - miRagen Therapeutics, Inc. - Nissan Chemical Industries, Ltd. - Proteon Therapeutics, Inc. - ReNeuron Group plc - RegenoCELL Therapeutics, Inc. - Sigma-Tau S.p.A. - Synthon BV - Theravasc, Inc. - Viromed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2j8flq/peripheral About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Medistem Presents Its ERC-124 Stem Cell Product at CRYO 2013
Marketwire - Wed Jul 31, 8:02AM CDT
Medistem, Inc. (PINKSHEETS: MEDS), announced today it's President and Chief Scientific Officer, Thomas E. Ichim, Ph.D., presented at the CRYO 2013 Conference held in Bethesda, Maryland on Monday July 29th.
Medistem Enters Collaboration With Boston Academic Teaching Hospital to Expand Preclinical Data in Type 1 Diabetes
Marketwire - Mon Jul 29, 8:01AM CDT
Medistem, Inc. (PINKSHEETS: MEDS) announced today it has entered into collaboration with Reza Abdi, M.D., Transplant Nephrologist at Brigham and Women's Hospital and Assistant Professor of Medicine, Harvard Medical School. Under the collaboration, the Company will provide Dr. Abdi with its Endometrial Regenerative Cells (ERCs) and it is expected that his research would support FDA clearance to initiate clinical trials to use ERCs as a treatment for Type 1 Diabetes. Currently, the Company has FDA clearance to initiate a dose-escalating Phase I clinical trial to use ERCs in patients with critical limb ischemia, a complication of diabetes.
Reminder -- Medistem to Host Investor Update Conference Call
Marketwire - Thu Jul 25, 8:02AM CDT
Medistem, Inc. (PINKSHEETS: MEDS), reminds investors that its Chief Executive Officer, Alan J. Lewis, Ph.D., will host a conference call today at 4:30 pm Eastern time (1:30 pm Pacific time). Dr. Lewis will provide a business update and discuss the Company's plans. Investors may participate either by phone or audio webcast.
Medistem Inc signs licensing agreement with Cytori Therapeutics Inc for autoimmune diseases
M2 - Fri Jul 19, 8:59AM CDT
Adult stem cell product company Medistem Inc (PINKSHEETS:MEDS) revealed on Thursday that it has licensed its exclusive rights to US Patent No. 8,241,621.
Medistem to Host Investor Update Conference Call
Marketwire - Fri Jul 19, 8:00AM CDT
Medistem, Inc. (PINKSHEETS: MEDS) today announced that Alan J. Lewis, Ph.D., the Company's Chief Executive Officer, will host a conference call at 4:30 pm Eastern time (1:30 pm Pacific time) on July 25, 2013. Dr. Lewis will provide a business update and discuss the Company's plans. Investors may participate either by phone or audio webcast.
Medistem and Cytori Therapeutics Enter Into Licensing Agreement
Marketwire - Thu Jul 18, 8:02AM CDT
Medistem, Inc. (PINKSHEETS: MEDS), today announced that it entered into an agreement granting Cytori Therapeutics, Inc. (NASDAQ: CYTX) a license and the exclusive rights to use Medistem's U.S. Patent No. 8,241,621, "Stem Cell Mediated Treg Activation" in the United States.
